Clinical Trials

Papillary Thyroid Microcarcinoma, Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT01709292 2026-04-16

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

24 enrolled

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT03048279 2026-04-16

Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

Active not recruiting

1,500 enrolled

Multiple Endocrine Neoplasia

NCT03110978 2026-04-16

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

140 enrolled

EndocrineThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Neuroendocrine

NCT07470489 2026-04-16

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

Thyroid Carcinoma, Anaplastic

NCT07532954 2026-04-16

The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support

25 enrolled

EndocrineGynecologic

Neuroendocrine Cervical Cancer

NCT07534371 2026-04-16

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

Active not recruiting

500 enrolled

Neuroendocrine Tumors

NCT05470595 2026-04-15

LCNEC-ALPINE

67 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine

NCT06066333 2026-04-15

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

Adrenocortical Carcinoma

NCT06638931 2026-04-15

ANTARES

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

28 enrolled

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT07485569 2026-04-15

REPOTHYROID-II

Phase 1 Not yet recruiting

10 enrolled

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT06607692 2026-04-14

LUPARPED

Phase 1/2 Recruiting

25 enrolled

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT06629220 2026-04-14

Co-creation of Tools for Men With Suicidal Thoughts and/or Behavior

Phase NA Completed

13 enrolled

Phase 1 Not yet recruiting

Suicide Prevention, Multiple Endocrine Neoplasia Type 1, Suicidal Ideation

NCT06941480 2026-04-14

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

Phase NA Not yet recruiting

Carcinoma, Neuroendocrine

NCT07529080 2026-04-14

Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial

142 enrolled

DermatologicEndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Melanoma, Testicular Neoplasms, Adenocarcinoma, Follicular

NCT04948437 2026-04-13

Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer

Active not recruiting

103 enrolled

Phase 1 Active not recruiting

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT05249114 2026-04-13

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

6 enrolled

Neuroendocrine Tumors

NCT06893783 2026-04-13

DeLLight

60 enrolled

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

NCT07521670 2026-04-13

STRAP

68 enrolled

Thyroid Cancer, Papillary, Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Recurrence

NCT04291885 2026-04-09

I-MAT

122 enrolled

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT05048901 2026-04-09

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Phase 1/2 Recruiting

49 enrolled

Neuroendocrine Tumors

NCT05696548 2026-04-09

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

51 enrolled

Thyroid Carcinoma, Anaplastic

NCT06141369 2026-04-09

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Phase NA Recruiting

21 enrolled

Adenoma, Islet Cell, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT03975231 2026-04-08

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Phase 1 Recruiting

6 enrolled

Thyroid Carcinoma, Anaplastic

NCT07516275 2026-04-07

Prospective Cohort Study of Pheochromocytoma/Paraganglioma

Not yet recruiting

200 enrolled

CNSEndocrine

Intraoperative Complications, Paraganglioma, Pheochromocytoma

NCT02673333 2026-04-06

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

39 enrolled 7 charts

Adrenocortical Carcinoma

NCT04412629 2026-04-06

Cabozantinib in High Grade Neuroendocrine Neoplasms

35 enrolled

High Grade Neuroendocrine Neoplasms

NCT05749289 2026-04-06

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

Phase 2/3 Recruiting

400 enrolled

Neuroendocrine Tumors

NCT07511660 2026-04-06

MUSE-OVARY

Enrolling by invitation

EndocrineGynecologic

Endocrine System Diseases, Primary Ovarian Insufficiency, Multiple Endocrine Neoplasia Type 1, Hot Flashes

NCT00107289 2026-04-02

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

200 enrolled

CNSEndocrine

Neuroblastoma, Pheochromocytoma

NCT04069299 2026-03-31

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Completed

30 enrolled

Carcinoma, Neuroendocrine

NCT06826170 2026-03-30

HYPOADENO

Phase NA Completed

25 enrolled

Phase 1/2 Active not recruiting

Pituitary Neoplasms

NCT04261855 2026-03-27

GoTHAM

19 enrolled

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT07493447 2026-03-25

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Phase EARLY_PHASE1 Not yet recruiting

30 enrolled

CNSEndocrine

Brain Neoplasms, Glioblastoma, Meningioma, Neoplasms, Neuroma, Acoustic, Pituitary Neoplasms

NCT04074642 2026-03-24

FIRST

Phase NA Completed

21 enrolled

Pituitary Neoplasms

NCT06430021 2026-03-24

PRO-NEM1

297 enrolled

Neuroendocrine Tumors

NCT00599092 2026-03-23

Pituitary Tumor Surveillance: Pathogenic Correlation

1,250 enrolled

Pituitary Neoplasms, Recurrence

NCT03244956 2026-03-23

MERAIODE

Phase 2 Completed

40 enrolled

Phase NA Active not recruiting

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

NCT04804371 2026-03-23

Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors

40 enrolled

Neuroendocrine Tumors

NCT04090034 2026-03-20

PRRT

EndocrineGastrointestinalNET

50 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06316895 2026-03-20

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

3,772 enrolled

Thyroid Cancer, Papillary

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT06122610 2026-03-19

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Phase 1 Recruiting

10 enrolled

Neuroendocrine Tumors

NCT05500391 2026-03-18

SUR-CAN